SCHEMBL1150160

SCHEMBL1150160

CCCCOC(=O)C1C(COC(=O)c2ccccc2)C1(C)C

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.50
TDP1 Q9NUW8 3/20 0.49
TSHR P16473 5/20 0.47
MAPK1 P28482 3/20 0.47
ESR1 P03372 3/20 0.47
CYP1A2 P05177 2/20 0.47
CYP2C19 P33261 2/20 0.47
CYP2D6 P10635 1/20 0.47
NR1H2 P55055 1/20 0.47
RNASEL Q05823 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
CYP3A4 P08684 3/20 0.46
CYP2C9 P11712 1/20 0.46
PDE4D Q08499 1/20 0.46
L3MBTL1 Q9Y468 3/20 0.46
POLB P06746 1/20 0.42
HPGD P15428 1/20 0.42
RECQL P46063 1/20 0.42
ALDH1A1 P00352 1/20 0.42
PPARG P37231 3/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1150127 0.96 TDP1 (0.51) LMNATDP1TSHRMAPK1ESR1
SCHEMBL1150535 0.95 TDP1 (0.50) LMNATDP1TSHRMAPK1ESR1
SCHEMBL1149784 0.94 LMNA (0.59) LMNATDP1TSHRMAPK1ESR1
SCHEMBL1150093 0.88 LMNA (0.46) LMNATDP1TSHRMAPK1SMN1; SMN2
SCHEMBL1150157 0.84 TSHR (0.46) LMNATDP1TSHRMAPK1CYP1A2
SCHEMBL1150260 0.82 LMNA (0.47) LMNATDP1TSHRMAPK1CYP1A2
SCHEMBL1150579 0.82 ALDH1A1 (0.43) LMNATDP1TSHRMAPK1ALDH1A1
SCHEMBL1685670 0.81 PDCD1 (0.42) LMNATDP1TSHRMAPK1SMN1; SMN2
SCHEMBL1150278 0.81 CES2 (0.42) LMNATDP1TSHRMAPK1CYP1A2
Hydrochloric Acid SCHEMBL6349703 0.79 LMNA (0.73) LMNATDP1TSHRMAPK1ESR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1950208-B1 PROCESS FOR PRODUCING 6,6-DIMETHYL-3-OXABICYCLO[3.1.0]HEXAN-2-ONE SUMITOMO CHEMICAL CO (JP) 2012-05-02 EP disclosed
US-7928253-B2 Method of producing 6,6-dimethyl-3-oxabicyclo[3.1.0]hexan-2-one SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-04-19 US disclosed
US-7893294-B2 Process for production of trans-2, 2-dimethyl-3-formylcyclopropanecarboxylic acid ester SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-02-22 US disclosed
US-20100168463-A1 METHOD OF PRODUCING 6,6-DIMETHYL-3-OXABICYCLO[3.1.0]HEXAN-2-ONE SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-07-01 US disclosed
US-20090314987-A1 PROCESS FOR PRODUCTION OF TRANS-2, 2-DIMETHYL-3-FORMYLCYCLOPROPANECARBOXYLIC ACID ESTER SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-12-24 US disclosed
EP-2053037-A1 PROCESS FOR PRODUCTION OF TRANS-2,2-DIMETHYL- 3-FORMYLCYCLOPROPANE CARBOXYLIC ACID ESTER Sumitomo Chemical Company, Limited (JP) 2009-04-29 EP disclosed
EP-1950208-A1 PROCESS FOR PRODUCING 6,6-DIMETHYL-3-OXABICYCLO[3.1.0]HEXAN-2-ONE Sumitomo Chemical Company, Limited (JP) 2008-07-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100168463-A1 METHOD OF PRODUCING 6,6-DIMETHYL-3-OXABICYCLO[3.1.0]HEXAN-2-ONE CYP1B1, HACL2, CMA1 LMNA 2892/4885TDP1 1116/4885TSHR 2332/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.